个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共7条记录   TEPLIZUMAB Anti-CD3 Human Monoclonal Antibody Treatment of Diabetes [作者：Davies, S,期刊：Drugs of the Future, 页码：467-469 , 文章类型： Article，,卷期：2010年35-6] The escalating statistics seen worldwide for autoimmune type I diabetes threaten to overwhelm healthcare systems, and therefore the importance of novel therapeutic strategies for this syndrome is growing. Teplizumab (MCA... ONCOVEXGM-CSF Armed Oncolytic Virus [作者：Senzer, N; Bedell, C; Nemunaitls, J,期刊：Drugs of the Future, 页码：449-455 , 文章类型： Article，,卷期：2010年35-6] The promise of cancer vaccines remains as yet unrealized as a reliable and effective therapeutic modality. There is now compelling evidence that collateral induction of antitumor immune responses contributes substantiall... RUXOLITINIB Tyrosine-Protein Kinase JAK1/2 Inhibitor Treatment of Myelofibrosis Treatment of Myeloproliferative Neoplasms Treatment of Psoriasis [作者：Campas-Moya, C,期刊：Drugs of the Future, 页码：457-465 , 文章类型： Article，,卷期：2010年35-6] Ruxolitinib (INCB-018424) is a selective tyrosine-protein kinase JAK1 and JAK2 inhibitor that acts by blocking the JAK/STAT pathway, which plays a key role in the signaling of many cytokines and growth factors involved i... ANTIBODY-MAYTANSINOID CONJUGATES: A NEW STRATEGY FOR THE TREATMENT OF CANCER [作者：Lambert, JM,期刊：Drugs of the Future, 页码：471-480 , 文章类型： Review，,卷期：2010年35-6] Early clinical development in the field of targeted delivery of cytotoxic drugs to tumors using antibodies failed to achieve effective, well-tolerated anticancer products. In recent years, several new highly potent cell-... PARP INHIBITION: ADVANCING THROUGH THE ONCOLYTIC ARENA [作者：Gien, LT; Mackay, HJ,期刊：Drugs of the Future, 页码：481-487 , 文章类型： Review，,卷期：2010年35-6] Poly(ADP-ribose)polymerase 1 (PARP-1) is an essential enzyme in the repair of single-strand breaks in DNA via the base excision repair pathway and has become an important novel target in cancer therapy. PARP inhibitors r... FAMILIAL DYSAUTONOMIA [作者：Chen, YT; Slaugenhaupt, SA,期刊：Drugs of the Future, 页码：489-494 , 文章类型： Article，,卷期：2010年35-6] Familial dysoutonomia (FD), also known as Riley-Day syndrome or recessive hereditary sensory and autonomic neuropathy type III (HSAN Ill), is caused by a single-base noncoding mutation in intron 20 (IVS20+6T > C) of the ... TARGETING LYSOPHOSPHOLIPID S1P RECEPTORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS [作者：Chun, J,期刊：Drugs of the Future, 页码：495-501 , 文章类型： Article，,卷期：2010年35-6] Sphingosine 1-phosphate (SIP) is an example of a lysophospholipid, a class of bioactive lipids with extracellular effects mediated by G protein-coupled receptors. There are five known S1P receptor subtypes, S1P(1-5). S1P...